Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus

Lisa Zhu, Manpreet Singh, Sonia Lele, Lori Sahakian, Jennifer Grossman, Bevra Hahn, Maureen McMahon

ABSTRACT

Objectives Traditional cardiovascular risk calculators such as the Framingham Risk Score (FRS) have been shown to underestimate risk in patients with SLE. The QRISK3 calculator is unique in including SLE and corticosteroid use as risk factors. This study aims to assess the validity of QRISK3 compared with other cardiovascular risk models in a cohort of patients with SLE in the USA.

Methods We studied a prospective cohort of 366 adult patients with SLE without history of any cardiovascular event and followed them for 10 years. We compared the diagnostic performance of QRISK3 with FRS, modified FRS, Atherosclerotic Cardiovascular Disease (ASCVD), and Predictors of Risk for Elevated Flares, Damage Progression and Increased Cardiovascular Disease in Patients with SLE (PREDICTS).

Results Sixty-four of the 366 patients (17.4%) experienced at least one cardiovascular event during the 10-year follow-up period. Of these patients 45% had a QRISK3 score >10%, whereas 20.5% of patients who did not have an event had a QRISK3 score >10% (p<0.001). The corresponding numbers for FRS, modified FRS, ASCVD and PREDICTS were 11.0% vs 7.2% (p=ns), 40.6% vs 28.0% (p=0.05), 12.2% vs 5.9% (p=ns), and 77% vs 32.1% (p<0.001), respectively. The areas under the receiver operating characteristic curve using QRISK3 >10% and high-risk PREDICTS were both larger than those using ASCVD >10%, FRS >10% and modified FRS >10%.

Conclusions Both QRISK3 and PREDICTS demonstrated better performance in predicting risk of cardiovascular disease in this cohort of patients with SLE compared with FRS, modified FRS and ASCVD.

INTRODUCTION

It has been well established that patients with SLE have an increased risk of developing cardiovascular disease (CVD). Studies have shown approximately twofold to tenfold increased risk of myocardial infarction (MI) in patients with SLE compared with patients in the general population. Notably the greatest relative risk for MI is seen in younger women, with one study reporting over 50-fold increased risk in women with SLE age 35–44 compared with age-matched controls. A similar pattern of increased risk has been reported with stroke.

This increased cardiovascular risk is not explained by the presence of traditional risk factors alone. SLE disease-related and therapy-related factors such as systemic inflammation and corticosteroid use are also thought to contribute to the process of accelerated atherosclerosis.

Traditional CVD risk calculators such as the Framingham Risk Score (FRS) and Atherosclerotic Cardiovascular Disease (ASCVD) calculators estimate a patient’s 10-year risk of CVD and have been validated for use in the general population. However, they do not
take into account the presence of inflammatory rheumatological diseases such as SLE. Consequently, their utility in this patient population has been questioned. The FRS in particular has been shown to underestimate risk in women with SLE.5

As a result, there has been growing interest in developing more accurate methods of CVD risk stratification in patients with SLE. Urowitz and colleagues6 determined that doubling the FRS improved risk prediction in patients with SLE and termed this formula the modified Framingham Risk Score (mFRS). Our group previously developed the PREDICTS (Predictors of Risk for Elevated Flares, Damage Progression and Increased Cardiovascular Disease in Patients with SLE) score, a panel of four biomarkers (proinflammatory high-density lipoprotein, leptin, homocysteine and soluble tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and two traditional cardiac risk factors (age ≥48 years and history of diabetes mellitus). We found that a high-risk PREDICTS profile, defined as either ≥3 positive biomarkers or ≥1 positive biomarker plus history of diabetes, was associated with 28-fold increased odds of longitudinal presence of carotid plaque and increased progression of intima-media thickness.7 More recently, we found that patients with high PREDICTS had a 3.7-fold increased risk of having a major adverse cardiovascular event (MACE).8

Published in 2007, the original QRISK calculator was developed and validated as a 10-year CVD risk prediction model for the UK primary care population. The newest version of the calculator, QRISK3, was published in 2017 and revised to incorporate several additional risk factors including SLE and corticosteroid use.9 The applicable age range was also extended to 25–84 years. QRISK3 has been shown to enhance CVD risk detection in a cohort of patients with SLE in the UK, but has not yet been studied in patients with SLE in the USA.10 QRISK3 was also examined in relation to subclinical parameters of atherosclerosis in a cohort of patients with SLE in Mexico. The authors found a significant correlation between QRISK3 score and mean carotid intima-media thickness, carotid pulse-wave velocity and distensibility.11

The purpose of this study was to assess the validity of QRISK3 compared with other cardiovascular risk calculators (FRS, mFRS and PREDICTS) in predicting CVD risk in a cohort of patients with SLE in the USA.

| Table 1 | Input for cardiovascular risk calculators |
|---------|------------------------------------------|
| QRISK3  | Framingham | ASCVD | PREDICTS |
| Age     | Age        | Age   | piHDL    |
| Sex     | Sex        | Sex   | Leptin   |
| Ethnicity | Smoking status | Race | Homocysteine |
| Diabetes | On blood pressure treatment | Diabetes | Soluble TWEAK |
| Smoking status | Total cholesterol | Smoking status | Age ≥48 years |
| Premature coronary artery disease in first-degree relative | HDL | On blood pressure treatment | Diabetes |
| CKD (stage 3, 4 or 5) | Systolic blood pressure | Total cholesterol |
| Atrial fibrillation | LDH |
| On blood pressure treatment | HDL |
| Migraines | Systolic blood pressure |
| Rheumatoid arthritis | Diastolic blood pressure |
| SLE | On statin |
| Severe mental illness | On aspirin |
| On atypical antipsychotic |
| On regular steroid tablets |
| Erectile dysfunction |
| Cholesterol to HDL ratio |
| Systolic blood pressure |
| SD of at least two most recent systolic blood pressure readings |
| Body mass index |

ASCVD, Atherosclerotic Cardiovascular Disease; CKD, chronic kidney disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; piHDL, proinflammatory high-density lipoprotein; PREDICTS, Predictors of Risk for Elevated Flares, Damage Progression and Increased Cardiovascular Disease in Patients with SLE; TWEAK, tumor necrosis factor-like weak inducer of apoptosis.
### METHODS

We studied a prospective cohort of 366 adult patients aged 25 and older with SLE without history of a cardiovascular event. Participants were recruited as part of the longitudinal ‘Biomarkers of Atherosclerosis in SLE’ cohort study from the rheumatology practices of the University of California Los Angeles and Cedars-Sinai Medical Center in Los Angeles from February 2004 to January 2019, as previously described.7

Baseline data on demographic factors, clinical diagnoses and clinical values were obtained via chart review and used to calculate QRISK3, ASCVD, FRS, mFRS and PREDICTS scores at the time of study enrolment. The various inputs into the QRISK3, ASCVD, FRS and PREDICTS calculators are listed in table 1. MACE was defined as death from any cause, coronary artery disease, MI, ischaemic stroke, transient ischaemic attack or peripheral arterial events (defined as arterial thrombosis requiring revascularisation). Patients under 25 years of age were excluded because this is the lower age limit for the QRISK3 calculator. ASCVD risk score could only be calculated for 43% (158 of 366 patients) because it has a lower age limit of 40 years.

χ² test was used for dichotomous variables and Student’s t-test for continuous variables. Receiver operating characteristic (ROC) curves were created using SPSS software (V.25) to evaluate the diagnostic performance of QRISK3, ASCVD, FRS and PREDICTS using a threshold of 10-year risk >10% for the first four calculators and ‘high-risk’ categorisation for PREDICTS.

### RESULTS

Baseline demographic data are shown in table 2. Of the 366 patients assessed in this study, 64 (17.4%) experienced at least one MACE during the 10-year follow-up period, for a total of 74 MACEs. The types of MACE are shown in table 3.

Of the patients who experienced at least one MACE, 45% had a QRISK3 score >10%, whereas 20.5% of patients who did not have an event had a QRISK3 score >10% from the rheumatology practices of the University of California Los Angeles and Cedars-Sinai Medical Center in Los Angeles from February 2004 to January 2019, as previously described.7
In comparison, 11% of patients who had at least one MACE had an FRS >10%, whereas 7.2% who did not have an event had an FRS >10% (p=ns). The corresponding numbers for mFRS, ASCVD and PREDICTS were 40.6% and 28.0% (p=0.05), 12.2% and 5.9% (p=ns), and 77% and 32.1% (p<0.001), respectively.

The area under the ROC using QRISK3 >10% (0.60) was larger than using ASCVD >10% (0.53), FRS >10% (0.52) and mFRS >10% (0.55), although it was slightly smaller than using high-risk PREDICTS score (0.65) (figure 1, table 4).

Using 95% CI, QRISK3 and PREDICTS outperformed the other calculators in terms of sensitivity and negative predictive value, although ASCVD had the highest specificity and positive predictive value (table 5).

Supplemental analyses performed on the ASCVD cohort of patients aged 40 and above showed similar findings in terms of area under the ROC (online supplemental tables 1 and 2).

**DISCUSSION**

Both QRISK3 and PREDICTS demonstrated better performance compared with ASCVD, FRS and mFRS in predicting risk of CVD in this cohort of patients with SLE. This is the first study to validate the use of the QRISK3 calculator in a longitudinal cohort of patients with SLE from the USA, and it indicates that QRISK3 may be a more useful risk assessment tool in this patient population compared with traditional calculators.

That said, the positive predictive value of QRISK3 >10% was only 32% and the area under the ROC only 0.60, reflecting limitations in its discriminatory ability. Although QRISK3 takes into account the presence of SLE and active corticosteroid use, it appears that this combination of variables is still neither sufficient nor precise enough to accurately gauge cardiovascular risk in this population. Given that QRISK3 and PREDICTS each performed better than the other calculators, perhaps a combination of the two approaches aiming to find the optimal combination of clinical and biochemical characteristics would produce better results.

There have yet to be clear recommendations on CVD prevention strategies (such as use of statins and aspirin for primary prevention) in SLE. Statins did not demonstrate a benefit in reducing subclinical atherosclerosis in a cohort of patients with SLE; however, they did decrease all-cause mortality in another cohort of SLE patients with hyperlipidaemia. At this point the consensus is to use them in accordance with current guidelines for the general population.

To help inform these questions, it is first necessary to create a more accurate CVD risk stratification tool to determine which patients in this population would be most likely to benefit from interventions or more frequent assessment. In a study by O’Neill and colleagues in London, institution of a CVD risk assessment protocol in their lupus clinic involving annual FRS calculation did not change management in most (96.5%) of cases, largely

| Table 4: Comparison of area under the ROC between risk calculators |
|--------------------------|--------------------------|--------------------------|--------------------------|
| Area under the ROC       | Asymptotic significance  | 95% CI                   |
| QRISK3 >10%              | 0.60                     | 0.05                     | 0.50 to 0.71             |
| QRISK3 >20%              | 0.57                     | 0.20                     | 0.46 to 0.67             |
| ASCVD >10%               | 0.53                     | 0.57                     | 0.43 to 0.64             |
| FRS >10%                 | 0.52                     | 0.75                     | 0.41 to 0.62             |
| Modified FRS >10%       | 0.55                     | 0.32                     | 0.45 to 0.66             |
| High-risk PREDICTS      | 0.65                     | 0.000                    | 0.55 to 0.74             |

ASCVD, Atherosclerotic Cardiovascular Disease; FRS, Framingham Risk Score; PREDICTS, Predictors of Risk for Elevated Flares, Damage Progression and Increased Cardiovascular Disease in Patients with SLE; ROC, receiver operating characteristic curve.

| Table 5: Comparison of sensitivity, specificity, PPV and NPV between risk calculators |
|--------------------------|--------------------------|--------------------------|--------------------------|
| Sensitivity % (95% CI)   | Specificity % (95% CI)   | PPV % (95% CI)           | NPV % (95% CI)           |
| QRISK3 >10%              | 45.3 (32.8 to 58.2)      | 79.5 (74.5 to 83.9)      | 32.2 (25.1 to 40.3)      | 87.1 (84.3 to 89.5) |
| QRISK3 >20%              | 21.4 (12.5 to 32.9)      | 94.6 (91.5 to 96.9)      | 48.4 (32.8 to 64.8)      | 83.8 (82.0 to 85.4) |
| ASCVD >10%               | 12.2 (4.1 to 26.2)       | 94.0 (88.1 to 97.6)      | 41.7 (19.4 to 68.0)      | 75.3 (72.9 to 77.5) |
| FRS >10%                 | 10.9 (4.5 to 21.3)       | 92.8 (89.1 to 95.5)      | 25.0 (12.9 to 42.9)      | 82.5 (81.2 to 83.8) |
| Modified FRS >10%       | 40.6 (28.5 to 53.6)      | 72.1 (66.5 to 77.2)      | 24.3 (18.5 to 31.3)      | 84.6 (81.6 to 87.2) |
| High-risk PREDICTS      | 73.4 (60.9 to 83.3)      | 65.2 (59.6 to 70.6)      | 30.9 (26.6 to 35.7)      | 92.1 (88.4 to 94.6) |

ASCVD, Atherosclerotic Cardiovascular Disease; FRS, Framingham Risk Score; PPV, positive predictive value; NPV, negative predictive value; PREDICTS, Predictors of Risk for Elevated Flares, Damage Progression and Increased Cardiovascular Disease in Patients with SLE.
because only a small fraction had FRS high enough to warrant consideration of lipid-lowering therapy and the majority of those patients were already on therapy on account of prior CVD or diabetes mellitus. Perhaps this would not have been the case using a more accurate risk stratification tool better tailored to the SLE population, which could identify patients missed by traditional risk calculators.

Our study is unique in being the first validation study of the QRISK3 calculator in patients with SLE in the USA. This was a prospective study that included a relatively large sample size. Additionally, we compared QRISK3 with a variety of other cardiovascular risk calculators.

This study has some limitations. While there is of course a strong predilection for SLE to affect women more than men, this ratio was exaggerated in our cohort, which included only 3% men, which may limit the generalisability of the findings to male patients. Our sample was not large enough to stratify patients by demographic factors such as ethnicity and disease duration, which could have been helpful since these factors affect CVD risk. There is the potential for selection bias in using data from a cohort designed to study atherosclerosis biomarkers, as well as biases associated with missing data since data were collected via chart review. The calculators we studied differ in the number of data elements required to generate the risk score, which affects their ease of use. QRISK3 requires more extensive chart review, while PREDICTs requires laboratory tests that are not yet fully available commercially.

We acknowledge that the qualitative definition of ‘high risk’ varies between the calculators being compared. The UK National Institute for Health and Care Excellence classifies patients with QRISK3 score ≥10% as being at high risk of CVD, whereas in the USA, where FRS and ASCVD are used, scores of ≥20% are considered high risk. However, we decided to use the same threshold of 10-year CVD risk of >10% for the QRISK3, FRS, mFRS and ASCVD to compare quantitative rather than qualitative risk. Additionally, very few patients in our cohort had a risk score of >20% (only 1 patient with the traditional FRS, 5 patients with mFRS, 1 patient with ASCVD and 31 with QRISK3). The ‘high-risk’ PREDICTs profile does not correlate with a specific 10-year CVD risk, but we used this categorisation based on the limits of the risk model.

In summary, the incorporation of SLE and corticosteroid use into the QRISK3 calculator appears to be a step in the right direction towards establishing a more accurate CVD risk stratification tool for patients with SLE, although further optimisation is needed.

**Author affiliations**

1. Medicine - Rheumatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA
2. Medicine, University of California Los Angeles, Los Angeles, California, USA

**Contributors** All authors take full accountability for the accuracy and integrity of this work. Study concept and design: MM, BH, JG and LZ. Acquisition of data: LZ, MS, LS and SL. Analysis and interpretation of data: MM, LZ, JG and BH. Drafting of the manuscript: LZ, MS and SL. Critical revision of the manuscript for important intellectual content: MM, JG, BH and LS. Guarantor: MM. All authors read and approved the manuscript.

**Funding** This project is supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (MM and JG) and the Alliance for Lupus Research (MM and BH). The study sponsors had no input into the study design, study procedures, data analysis or interpretation of the results.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study involves human participants and was approved by the University of California, Los Angeles Institutional Review Board (ID number 13-001285). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. De-identified participant data are available upon reasonable request. Data from this project can be considered by release if the appropriate institutional review board and publication clearances have been made. MM has access to all data (mmcmahon@mednet.ucla.edu).

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially. License the derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use and license their derivative works on different terms, provided the original work is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Lisa Zhu http://orcid.org/0000-0001-9855-7285
Maureen McMahon http://orcid.org/0000-0002-2910-7640

**REFERENCES**

1. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77–85.
2. Manzi S, Meilahn EN, Rairie JE, et al. Age-Specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408–15.
3. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008;117:743–53.
4. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American heart association Task force on practice guidelines. J Am Coll Cardiol 2014;63:2935–59.
5. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum 2003;48:3159–67.
6. Urowitz MB, Ibañez D, Su J, et al. Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol 2016;43:875–9.
7. McMahon M, Skaggs BJ, Grossman JM, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 2014;66:130–9.
8. Skaggs BJ, Grossman J, Sahakian L, et al. A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol 2021;3:209–20.
9 Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ* 2017;357:j2099.
10 Edwards N, Langford-Smith AWW, Parker BJ, et al. QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. *Lupus Sci Med* 2018;5:e000272.
11 Vázquez-Del Mercado M, Perez-Vazquez FdeJ, Gomez-Bañuelos E, et al. Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus. *PLoS One* 2018;13:e0207520.
12 Petri MA, Kiani AN, Post W, et al. Lupus atherosclerosis prevention study (LAPS). *Ann Rheum Dis* 2011;70:760–5.
13 Yu H-H, Chen P-C, Yang Y-H, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. *Atherosclerosis* 2015;243:11–18.
14 O’Neill SG, Pego-Reigosa JM, Hingorani AD, et al. Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. *Rheumatology* 2009;48:573–5.